Global Cardiology Academy

Welcome to Global
Cardiology Academy

Enhance your cardiology practice with CME and
tools focused on heart health management.

Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
Cardiology
Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
- Kausik Ray, MBChB, MD, MPhil
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
Cardiology
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
- Kausik Ray, MBChB, MD, MPhil
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
CME/CE
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
- Daniel Judge, MD
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
CME/CE
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
0.25 credits
- Amy Mottl, MD, MPH
- Prof. Christoph Wanner
0.25 credits
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
CME/CE
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
1.00 credit
- Muthiah Vaduganathan, MD, MPH
- Anuradha Lala-Trindade, MD
- Brendon Neuen, MBBS, PhD
1.00 credit
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
MinuteCE®
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
MinuteCE®
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
MinuteCE®
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit

Programs

MinuteCE®
From Risk to Results: Cases in ASCVD Prevention and Treatment
1.00 credit 10 episodes
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 credit 10 episodes
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
MinuteCE®
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Bridging ASCVD Care Between Academic and Rural Settings
Bridging ASCVD Care Between Academic and Rural Settings
MinuteCE®
Bridging ASCVD Care Between Academic and Rural Settings
1.00 program credit
- Rishi Wadhera, MD, MPP, Mphil
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
1.00 program credit
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
MinuteCE®
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
1.00 program credit
- Rishi Wadhera, MD, MPP, Mphil
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
1.00 program credit
Statins and Safety: What the Data Say About Dementia, Cancer, and More
Statins and Safety: What the Data Say About Dementia, Cancer, and More
MinuteCE®
Statins and Safety: What the Data Say About Dementia, Cancer, and More
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Target in Sight: Escalating Therapy to Reach LDL-C Goals
Target in Sight: Escalating Therapy to Reach LDL-C Goals
MinuteCE®
Target in Sight: Escalating Therapy to Reach LDL-C Goals
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Albuminuria Change and Finerenone's Effect on CV Outcomes
Albuminuria Change and Finerenone's Effect on CV Outcomes
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)
Albuminuria Change and Finerenone's Effect on CV Outcomes
- Finnian R. McCausland, MD
Complexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Complexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Heart Matters
Complexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
- Gautam Nayak, MD

Clinical Practice

CETP Inhibition with Obicetrapib: Implications for Cardiovascular Event Prevention
CETP Inhibition with Obicetrapib: Implications for Cardiovascular Event Prevention
Cardiology
CETP Inhibition with Obicetrapib: Implications for Cardiovascular Event Prevention
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Cardiology
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
- Javed Butler, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
CME/CE
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
- Kevin Alexander, MD
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
CME/CE
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
- Ahmad Masri, MD, MS
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
CME/CE
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
0.25 credits
- prof. Hiddo Heerspink
- Jennifer B. Green, MD
0.25 credits
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
CME/CE
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
0.25 credits
- Robert J. Mentz, MD, FHFSA, FACC, FAHA
- Piotr Ponikowski, MD, PhD, FESC, FHFA
0.25 credits
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
- John Ostrominski
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
- Jonathan Cunningham, MD

CME

Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CE
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
0.50 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Amy Mottl, MD, MPH
- Muthiah Vaduganathan, MD, MPH
0.50 credits
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
MinuteCE®
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
- Finnian R. McCausland, MD
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
CME/CE
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
1.00 credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 credit
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
CME/CE
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
- Stefan D. Anker, MD, PhD
- Mahir Karakas, MD, PhD, MBA
Tailoring Treatment for Optimal Outcomes in Patients With AAV
Tailoring Treatment for Optimal Outcomes in Patients With AAV
MinuteCE®
Tailoring Treatment for Optimal Outcomes in Patients With AAV
0.75 program credits
- Bernhard Hellmich, MD
- Andreas Kronbichler, MD
0.75 program credits
Trade off: Ischemic/Thrombotic vs Bleeding  
Trade off: Ischemic/Thrombotic vs Bleeding  
MinuteCE®
Trade off: Ischemic/Thrombotic vs Bleeding  
1.00 program credit
- Renato D. Lopes, MD, MHS, PhD
1.00 program credit